Biomin commits to the AMR Challenge, a multi-stakeholder initiative led by the U.S. Centers for Disease Control and Prevention (CDC) for governments, private industries and non-governmental organizations worldwide to make progress against antimicrobial resistance.
In particular, the company commits to “expanding the reduction of non-medically necessary use of antibiotic feed solutions across the agriculture sector globally.” This will be accomplished primarily through greater adoption of the firm’s biotech-based solutions that cover mycotoxin risk management, gut performance and animal nutrition. “In order to preserve the medicinal value of antibiotics, we need to use less of them. That means using alternatives to promote growth and maintain healthy animals,” stated Dr Jan Vanbrabant, Managing Director of BIOMIN and Executive Board Chairman of ERBER Group. “We use unparalleled technologies to deliver effective, easy-to-use solutions to the feed and animal protein sectors that bring such benefits and generate return on investment for our clients,” he added.
The commitment to the AMR Challenge coincides with the firm’s goal to support sustainable agriculture, which entails the responsible use of antibiotics, enhanced profits and productivity, producing affordable food, generating employment, reducing the environmental footprint of farm animals and ensuring their health and welfare.
Watch video here.
